Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159209 · ClinicalTrials.gov registry record
The Drug Induced Renal Injury Consortium
A clinical trial of Acute Kidney Injury and Kidney Disease, sponsored by Ravindra Mehta.
- Completed
- Registry status
- 634
- Enrollment target
- 18
- Study locations
NCT02159209 is a study of Acute Kidney Injury and Kidney Disease that has completed, run by Ravindra Mehta. The registered enrollment target is 634 participants, below the 2,322-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (73% lower). The trial reports 18 study locations across 11 states.
The verdict
NCT02159209, a study of Acute Kidney Injury and Kidney Disease, has completed, sponsored by Ravindra Mehta.
- COMPLETED
- Registry status
- 634 participants
- Enrollment target
- 18
- Study locations
Study Summary
Some medications are known to cause kidney damage because the person is allergic to the medication while others cause direct damage to the kidney because they are toxic at certain concentrations. Risk factors for developing kidney damage have been identified for some medications but not for all. Patients who are exposed to these important medications and develop problems with their kidneys may have some genetic risk. The purpose of this study is to determine the genetic risk factors for drug induced kidney injury. A better understanding of the role of genetics for the development of kidney injury from medications will allow us to better select medications, improve effectiveness of treatment and minimize harm.
Conditions Studied
Study Locations (18)
Other
- Universidad del Valle, Cochabamba - Cochabamba
- Universidad de Los Andes - Santiago
- Postgraduate Institute of Research, Chandigarh - Chandigarh
- Royal Free Hospital - London
- Guy's & St Thomas's Hospital - London
- University of Nottingham - Nottingham
California
- University of California, San Diego - San Diego
- Rady Children's Hospital - San Diego
New York
- St. Peter's Hospital - Albany
- Jacobi Medical Center - New York
Alabama
- University of Alabama, Birmingham - Birmingham
Colorado
- University of Colorado - Aurora
Michigan
- University of Michigan - Ann Arbor
Ohio
- Cincinnati Children's Hospital - Cincinnati
Quebec
- Hopital Sacre Coeur & Universite de Montreal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 634 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159209
The ClinicalTrials.gov registry entry for NCT02159209 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 634 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,322-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (73% lower). The listed sponsor is Ravindra Mehta, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 0 interventions.
NCT02159209 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT02159209 about?
NCT02159209 is a clinical study titled "The Drug Induced Renal Injury Consortium". Some medications are known to cause kidney damage because the person is allergic to the medication while others cause direct damage to the kidney because they are toxic at certain concentrations. Risk factors for developing kidney damage have been identified for some medications but not for all. Pat...
What is the current status of trial NCT02159209?
This trial is currently completed. The enrollment target is 634 participants. The study started on 2013-02. Estimated completion is 2015-12.
What conditions does trial NCT02159209 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Kidney Disease, Kidney Failure, Acute Kidney Failure, Adverse Drug Reaction.
Who is sponsoring clinical trial NCT02159209?
This trial is sponsored by Ravindra Mehta, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02159209 being conducted?
This trial has 18 study locations across Alabama, California, Colorado, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.